Latest Breaking News On - ஜெர்மனி அடிப்படையிலானது மெர்க் - Page 1 : comparemela.com
Can mRNA vaccines do for cancer what they did with Covid-19?
medcitynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medcitynews.com Daily Mail and Mail on Sunday newspapers.
Global New Material (6166 HK) IPO: Leading Consumable Material Producer to Benefit with Listing
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Corrections and clarifications
theguardian.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theguardian.com Daily Mail and Mail on Sunday newspapers.
Summary
The new entity will largely be led by Pfizer executives and will be registered in Delaware. The new entity is anticipated to leverage the stand-alone Mylan infrastructure consisting of roughly 55 manufacturing and research and development facilities and that were largely acquired, including Matrix Laboratories and the generics business of Germany-based Merck KGaA. The combined portfolio will consist of the mature Upjohn drugs with notably better economics and Mylan s portfolio of more than 7,500 generic, specialty, and over-the-counter active ingredients and medicines, including EpiPen (treatment for anaphylaxis acquired through the Merck KGaA transaction). Unlike its generic peers, the company has made the most progress on the biosimilar front.
MilliporeSigma expands Wisconsin operations
Share This Article
MilliporeSigma, an industry-leading life sciences company that provides contract pharmaceutical manufacturing services, currently has four biochemical production and pharmaceutical ingredient manufacturing facilities in Wisconsin and recently announced a $65 million expansion of the facility, in Verona, Wisconsin, a project expected to create approximately 50 new jobs starting this year.
The company’s expansion plans include increasing the company’s antibody-drug conjugate (ADC) manufacturing capacity and adding a 70,000-square-foot highly potent active pharmaceutical ingredient manufacturing facility. These additions will accommodate projected growth and provide an audit-ready facility that meets customer and internal quality requirements.
WEDC has authorized up to $200,000 in state income tax credits over the next three years, contingent upon the number of jobs created.